SGY.TO -0.42CJ.TO -0.35GEI.TO -0.79TLN -10.16RITM -0.15UBER -3.81AAAU 1.645MNT.TO 1.18
Eli Lilly & Co. (LLY)

NYSE:LLY

Eli Lilly & Co. (LLY)

1,169.86
+54.18 (4.86%)
as of Aug 5, 2026, 8:00:00 pm Market Open.
220 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 5, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Eli Lilly & Co. (LLY) is positioning itself strongly in the healthcare market, particularly in the GLP-1 drug sector, leading to significant earnings growth expectations of around 25% annually in the coming years. Analysts emphasize LLY's competitive edge over Novo Nordisk (NVO), noting that their innovations have resulted in increased market share, particularly with the anticipated approval of an oral weight-loss pill. Many highlights include a solid pipeline of drugs and an expanding presence in treatment areas such as obesity and diabetes, while recent momentum has seen the stock breaking into new highs. However, there's caution over potential valuations due to the stock’s strong performance and the RSI nearing overbought territory. Overall, LLY is seen as a reliable long-term growth story amid a transformation from a traditional steady income earner to a fast-growing pharmaceutical company.

consensus icon
Consensus
Bullish
valuation icon
Valuation
Overvalued
review icon
Similar
ThermoFisher, TMO
BUY

Eli Lilly & Co.(LLY)

Oct 19, 2020
He owns a basket. He owns this one for their oncology division. He has not owned it for anything COVID-related. Sometimes it is better to buy a basket of these companies.
Photo of Robert LauzonRobert Lauzon
Owned
Unlock Rating
$143.86

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Sep 21, 2020
They just released very promising data on their breast cancer drug (the previous update in June saw the stock pop), but the stock still dropped in price today. This is strange and undeserved, but the selling won't last.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$151.18

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Aug 02, 2019
He sold it several months ago, because it outperformed like crazy in late-2018. That was expected, because healthcare is the most defensive sector and Q4 was a bear market with fears of a recession. LLY made an acquisition in oncology and one of their big drugs got withdrawn. Novo Nordisk may launch a diabetes drug in September to fcompete with LLY.
Photo of David FingoldDavid Fingold
No
Unlock Rating
$111.60

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Jul 08, 2019
It has one of the best growth profiles on the street with EPS growth at 10%. It trades at a premium to its peers, though. They have some potential blockbuster drugs focused on diabetes and heart disease. Itt depends on the effectiveness of that drug. Now is a good entry point. (Analysts’ price target is $125.81)
Photo of Jamie Murray Jamie Murray
Owned
Unlock Rating
$111.52

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

May 30, 2019
The whole drug industry is a slow growth one. It is difficult to get top line growth. That growth tends to come from a revolving set of assets. MRK-N has a bit of a leg up and is growing rapidly. It has a long runway before patent expiration. He prefers MRK-N.
Photo of Gordon ReidGordon ReidUnlock Rating
$115.90

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Eli Lilly & Co.(LLY)

May 03, 2019
Likes it. One of better growth profiles for large cap pharma. Exceptional job building out the pipeline in oncology and diabetes. Cardiac drug seems like becoming the standard of care. Some hiccups, but the market gave them a pass. 14-15% EPS growth. 17x next year's earnings. Make sure the launches are on track next quarter.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$116.97

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Eli Lilly & Co.(LLY)

Apr 15, 2019
(A Top Pick Dec 18/18, Up 17%) He owned a lot in this sector and sold on strength. He would have no problem buying it if he did not have a healthcare stock. It is one of the few areas that are truly in a secular bull market.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
No
Unlock Rating
$124.08

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Eli Lilly & Co.(LLY)

Apr 08, 2019
He is not yet taking profits. They dominate the insulin business. As the world gets larger and overeats … The stock takes patience. It will probably sell off with the market.
Photo of Bruce MurrayBruce Murray
Owned
Unlock Rating
$127.13

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Eli Lilly & Co.(LLY)

Mar 22, 2019
What does the increase in volume signal? Some technicians see volume as confirmation. You need volume spike to confirm a move. On the downside, volume doesn't tell you a lot, as things can start slowly. So don't read too much into it. If this stock comes back down to north of $105, a lot of investors would probably come back in. A good name, if you didn't want to buy XLD or HHL.T.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSIUnlock Rating
$128.30

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Dec 18, 2018
Broke out over the summer. Healthcare is one of the few sectors that's in a secular bull market, and is even making new highs in the current bull market. LLY tends to beat guidance. They deliver. This trend should continue into 2019. (Analysts’ price target is $114.96)
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
Owned
Unlock Rating
$106.50

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Oct 18, 2018

Just bought it. They have come with new pills for diabetes with huge potential. Yield of 2.0%. Drugs stocks are in favor. Likes the sector.

Photo of Bruce MurrayBruce Murray
Owned
Unlock Rating
$113.31

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Eli Lilly & Co.(LLY)

May 10, 2017

He likes this. They have a diversified pipeline. Had a couple of mishaps. A fair amount was baked into their Alzheimer’s drug in November, and they kind of walked away from it. Also, their anti-inflammatory did not get FDA approval. There was some positive data from their Monarch pretrial, phase 3 of breast cancer. This is a very strong hold.

Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$81.05

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Nov 24, 2016

The whole drug sector in general has been suffering badly. For the last decade or so, it has been almost impossible to raise drug prices. The election of Donald Trump may be favourable to the drug sector. They are all suffering with the increasing movement of generic drugs, and all have relatively weak pipelines. Most of the pharma sector is struggling, and even cutting back on research and development. He would look elsewhere.

Photo of Lorne SteinbergLorne SteinbergUnlock Rating
$68.00

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Apr 13, 2016

Right now Pharma is struggling. This company has cash generation and a diversified portfolio lineup. There are a number of factors for right now, but healthcare is facing a lot of headwinds now. You should be looking at this in the 10s, maybe low teens growth profile.

Photo of Cameron HurstCameron Hurst
No
Unlock Rating
$75.16

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Dec 12, 2013

One of the laggards in the pharma group. If a company can’t do well in a good market, then it is time to move on. Prefers JNJ-N for pharma exposure.

Photo of David BurrowsDavid BurrowsUnlock Rating
$49.23

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
Showing 166 to 180 of 208 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AMD -36.53$482.05
CME 0$
SHOP 20.94$144.24
ELAN 0.62$26.22
ANET 6.8$197.31
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

SGY.TO -0.42$9.75
CJ.TO -0.35$10.73
GEI.TO -0.79$30.64
TLN -10.16$329.84
RITM -0.15$10.1

Popular Articles

Latest Sell Signals

CVS -5.3$99.12
VET.TO -0.71$14.8
TOU.TO 0.36$13.75
AMD -36.53$482.05
PFE 0.4$25.81

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Jerome Hass

Jerome Hass

Lightwater Partners

Mike Vinokur, CFA, CMT, and CFP

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Monthly Gems by Allan Tong

The Monthly Gems by Allan Tong

Stockchase

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like